The Rheumatology Market is expected to register a CAGR of 6.2% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The Rheumatology Market report covers segmental analysis by Drug Class (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Uric Acid Drugs, Disease Modifying Anti-Rheumatic Drugs (DMARDs)); Disease Indication (Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Ankylosing Spondylitis); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Geography (North America, Europe, Asia Pacific, and South and Central America). The global analysis is further broken down at the regional level and major countries. The report Offers the Value in US$ for the above analysis and segments.
Purpose of the ReportThe report Rheumatology Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Rheumatology Market Segmentation
Drug Class- Nonsteroidal Anti-Inflammatory Drugs
- Corticosteroids
- Uric Acid Drugs
- Disease Modifying Anti-Rheumatic Drugs
- Rheumatoid Arthritis
- Osteoarthritis
- Gout
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Strategic Insights
Rheumatology Market Growth Drivers- Expanding Awareness and Education on Rheumatic Disorders: Increased awareness of rheumatic diseases among the general population and healthcare providers is a critical driver of the rheumatology market. Patient advocacy groups, healthcare initiatives, and social media have played an essential role in educating both patients and clinicians about early signs and symptoms of rheumatic diseases. This heightened awareness encourages early treatment and ongoing management, thereby expanding market demand for rheumatology drugs and services.
- Growing Geriatric Population: The global aging population is directly contributing to the rise in the incidence of rheumatic diseases, as they are more prevalent among older individuals. Osteoarthritis, rheumatoid arthritis, and other degenerative joint diseases are particularly common in this demographic, increasing the need for medical interventions. The geriatric population's growing healthcare demands are thus acting as a key growth driver in the rheumatology market, fueling the need for targeted therapies and innovative treatments that cater specifically to the elderly.
- Expanding Availability of Non-Pharmacological Treatments: Non-pharmacological interventions such as physical therapy, dietary changes, exercise programs, and assistive devices are gaining more acceptance in rheumatology. These interventions complement pharmacological treatments and focus on improving mobility and function, reducing pain, and enhancing overall well-being. As patients increasingly seek a comprehensive approach to managing their condition, the availability of these therapies is driving the growth of the rheumatology market, particularly in developed regions.
- Rise of Gene and Cell-Based Therapies: The rheumatology market is poised for a breakthrough with the rise of gene and cell-based therapies. These therapies, which aim to modify genetic material or utilize stem cells to repair or replace damaged tissues, are gaining traction for treating autoimmune and inflammatory diseases. As research continues to evolve, gene-editing techniques like CRISPR and stem cell treatments could offer transformative solutions for patients with conditions such as rheumatoid arthritis and lupus. This promising trend will lead to more targeted, long-term treatments, positioning gene and cell-based therapies as key drivers of the future rheumatology market.
- Focus on Disease Modifying Anti-Rheumatic Drugs (DMARDs): Disease-modifying anti-rheumatic drugs (DMARDs) are the cornerstone of treating autoimmune rheumatic diseases, and ongoing advancements in this class of drugs will shape the rheumatology market. Future trends suggest more potent and targeted DMARDs that address the underlying causes of disease progression, minimizing side effects and improving patient outcomes. Both traditional and biologic DMARDs will continue to evolve, with a focus on achieving remission and improving long-term quality of life for patients. The next generation of DMARDs will likely lead to better patient management, a critical factor in the market's future growth.
- Expansion of Non-Pharmacological Treatment Options: There is a growing trend toward combining pharmacological treatments with non-pharmacological interventions in managing rheumatic diseases. The future of the rheumatology market will likely see a broader range of complementary therapies such as physical therapy, acupuncture, dietary interventions, and personalized exercise regimens. These therapies can improve function, reduce pain, and slow disease progression. As patients seek holistic treatment options, non-pharmacological therapies will be integrated into comprehensive care plans, promoting better outcomes and expanding the rheumatology market.
- Gene and Cell-Based Therapies for Autoimmune Diseases: The emergence of gene and cell-based therapies presents a promising opportunity in the rheumatology market. For diseases like rheumatoid arthritis, lupus, and spondyloarthritis, these therapies hold the potential to address underlying genetic or cellular causes rather than just symptoms. Investing in gene-editing technologies like CRISPR or stem cell-based regenerative treatments opens new avenues for market players to develop novel therapies, potentially revolutionizing the way rheumatic diseases are treated and providing long-term, disease-modifying outcomes for patients.
- Preventive Care and Early Intervention Models: With the growing focus on prevention and early intervention in rheumatology, there is an opportunity for stakeholders to create programs that emphasize early detection, lifestyle modifications, and preventive treatments. As research supports the effectiveness of early treatment in reducing long-term disability, new models of care that prioritize prevention can emerge. This may include routine screening for at-risk populations or mobile apps that help monitor symptoms. Such opportunities will shape the future of the rheumatology market by shifting from reactive to proactive care, thereby reducing overall healthcare costs and improving patient quality of life.
- Regulatory Advancements and Fast-Track Approvals: Regulatory bodies around the world, including the FDA and EMA, are increasingly offering fast-track approvals for innovative therapies addressing serious diseases like rheumatoid arthritis and lupus. This regulatory environment presents an opportunity for companies in the rheumatology market to expedite the development and commercialization of new drugs. With the promise of quicker market access thatate the regulatory landscape effectively will have a competitive edge, allowing itto capitalize on unmet needs in the rheumatology space faster than ever before.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Rheumatology Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Rheumatology Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Rheumatology Market is expected to register a CAGR of 6.2% from 2025-2031.
The major factors impacting the Rheumatology Market are: Expanding Awareness and Education on Rheumatic Disorders, Growing Geriatric Population and Expanding Availability of Non-Pharmacological Treatments
Key future trends in this market are - Rise of Gene and Cell-Based Therapies, Focus on Disease Modifying Anti-Rheumatic Drugs (DMARDs and Expansion of Non-Pharmacological Treatment Options
Key companies of this market are: Merck KGaA, Thermo Fisher Scientific, Inc., Horizon Discovery Ltd., Synlogic, QIAGEN, GeneCopoeia, Inc., New England Biolabs, Quantabio, NanoString
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Rheumatology Market - By Drug Class
1.3.2 Rheumatology Market - By Disease Indication
1.3.3 Rheumatology Market - By Distribution Channel
1.3.4 Rheumatology Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. RHEUMATOLOGY MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. RHEUMATOLOGY MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. RHEUMATOLOGY MARKET - GLOBAL MARKET ANALYSIS
6.1. RHEUMATOLOGY - GLOBAL MARKET OVERVIEW
6.2. RHEUMATOLOGY - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. RHEUMATOLOGY MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAID'S)
7.3.1. Overview
7.3.2. Nonsteroidal Anti-Inflammatory Drugs (NSAID's) Market Forecast and Analysis
7.4. CORTICOSTEROIDS
7.4.1. Overview
7.4.2. Corticosteroids Market Forecast and Analysis
7.5. URIC ACID DRUGS
7.5.1. Overview
7.5.2. Uric Acid Drugs Market Forecast and Analysis
7.6. DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (DMARD'S)
7.6.1. Overview
7.6.2. Disease Modifying Anti-Rheumatic Drugs (DMARD's) Market Forecast and Analysis
8. RHEUMATOLOGY MARKET - REVENUE AND FORECASTS TO 2028 - DISEASE INDICATION
8.1. OVERVIEW
8.2. DISEASE INDICATION MARKET FORECASTS AND ANALYSIS
8.3. RHEUMATOID ARTHRITIS
8.3.1. Overview
8.3.2. Rheumatoid Arthritis Market Forecast and Analysis
8.4. OSTEOARTHRITIS
8.4.1. Overview
8.4.2. Osteoarthritis Market Forecast and Analysis
8.5. GOUT
8.5.1. Overview
8.5.2. Gout Market Forecast and Analysis
8.6. PSORIATIC ARTHRITIS
8.6.1. Overview
8.6.2. Psoriatic Arthritis Market Forecast and Analysis
8.7. ANKYLOSING SPONDYLITIS
8.7.1. Overview
8.7.2. Ankylosing Spondylitis Market Forecast and Analysis
9. RHEUMATOLOGY MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACY
9.3.1. Overview
9.3.2. Hospital Pharmacy Market Forecast and Analysis
9.4. RETAIL PHARMACY
9.4.1. Overview
9.4.2. Retail Pharmacy Market Forecast and Analysis
9.5. ONLINE PHARMACY
9.5.1. Overview
9.5.2. Online Pharmacy Market Forecast and Analysis
10. RHEUMATOLOGY MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Rheumatology Market Overview
10.1.2 North America Rheumatology Market Forecasts and Analysis
10.1.3 North America Rheumatology Market Forecasts and Analysis - By Drug Class
10.1.4 North America Rheumatology Market Forecasts and Analysis - By Disease Indication
10.1.5 North America Rheumatology Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Rheumatology Market Forecasts and Analysis - By Countries
10.1.6.1 United States Rheumatology Market
10.1.6.1.1 United States Rheumatology Market by Drug Class
10.1.6.1.2 United States Rheumatology Market by Disease Indication
10.1.6.1.3 United States Rheumatology Market by Distribution Channel
10.1.6.2 Canada Rheumatology Market
10.1.6.2.1 Canada Rheumatology Market by Drug Class
10.1.6.2.2 Canada Rheumatology Market by Disease Indication
10.1.6.2.3 Canada Rheumatology Market by Distribution Channel
10.1.6.3 Mexico Rheumatology Market
10.1.6.3.1 Mexico Rheumatology Market by Drug Class
10.1.6.3.2 Mexico Rheumatology Market by Disease Indication
10.1.6.3.3 Mexico Rheumatology Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Rheumatology Market Overview
10.2.2 Europe Rheumatology Market Forecasts and Analysis
10.2.3 Europe Rheumatology Market Forecasts and Analysis - By Drug Class
10.2.4 Europe Rheumatology Market Forecasts and Analysis - By Disease Indication
10.2.5 Europe Rheumatology Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Rheumatology Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Rheumatology Market
10.2.6.1.1 Germany Rheumatology Market by Drug Class
10.2.6.1.2 Germany Rheumatology Market by Disease Indication
10.2.6.1.3 Germany Rheumatology Market by Distribution Channel
10.2.6.2 France Rheumatology Market
10.2.6.2.1 France Rheumatology Market by Drug Class
10.2.6.2.2 France Rheumatology Market by Disease Indication
10.2.6.2.3 France Rheumatology Market by Distribution Channel
10.2.6.3 Italy Rheumatology Market
10.2.6.3.1 Italy Rheumatology Market by Drug Class
10.2.6.3.2 Italy Rheumatology Market by Disease Indication
10.2.6.3.3 Italy Rheumatology Market by Distribution Channel
10.2.6.4 Spain Rheumatology Market
10.2.6.4.1 Spain Rheumatology Market by Drug Class
10.2.6.4.2 Spain Rheumatology Market by Disease Indication
10.2.6.4.3 Spain Rheumatology Market by Distribution Channel
10.2.6.5 United Kingdom Rheumatology Market
10.2.6.5.1 United Kingdom Rheumatology Market by Drug Class
10.2.6.5.2 United Kingdom Rheumatology Market by Disease Indication
10.2.6.5.3 United Kingdom Rheumatology Market by Distribution Channel
10.2.6.6 Rest of Europe Rheumatology Market
10.2.6.6.1 Rest of Europe Rheumatology Market by Drug Class
10.2.6.6.2 Rest of Europe Rheumatology Market by Disease Indication
10.2.6.6.3 Rest of Europe Rheumatology Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Rheumatology Market Overview
10.3.2 Asia-Pacific Rheumatology Market Forecasts and Analysis
10.3.3 Asia-Pacific Rheumatology Market Forecasts and Analysis - By Drug Class
10.3.4 Asia-Pacific Rheumatology Market Forecasts and Analysis - By Disease Indication
10.3.5 Asia-Pacific Rheumatology Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Rheumatology Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Rheumatology Market
10.3.6.1.1 Australia Rheumatology Market by Drug Class
10.3.6.1.2 Australia Rheumatology Market by Disease Indication
10.3.6.1.3 Australia Rheumatology Market by Distribution Channel
10.3.6.2 China Rheumatology Market
10.3.6.2.1 China Rheumatology Market by Drug Class
10.3.6.2.2 China Rheumatology Market by Disease Indication
10.3.6.2.3 China Rheumatology Market by Distribution Channel
10.3.6.3 India Rheumatology Market
10.3.6.3.1 India Rheumatology Market by Drug Class
10.3.6.3.2 India Rheumatology Market by Disease Indication
10.3.6.3.3 India Rheumatology Market by Distribution Channel
10.3.6.4 Japan Rheumatology Market
10.3.6.4.1 Japan Rheumatology Market by Drug Class
10.3.6.4.2 Japan Rheumatology Market by Disease Indication
10.3.6.4.3 Japan Rheumatology Market by Distribution Channel
10.3.6.5 South Korea Rheumatology Market
10.3.6.5.1 South Korea Rheumatology Market by Drug Class
10.3.6.5.2 South Korea Rheumatology Market by Disease Indication
10.3.6.5.3 South Korea Rheumatology Market by Distribution Channel
10.3.6.6 Rest of Asia-Pacific Rheumatology Market
10.3.6.6.1 Rest of Asia-Pacific Rheumatology Market by Drug Class
10.3.6.6.2 Rest of Asia-Pacific Rheumatology Market by Disease Indication
10.3.6.6.3 Rest of Asia-Pacific Rheumatology Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Rheumatology Market Overview
10.4.2 Middle East and Africa Rheumatology Market Forecasts and Analysis
10.4.3 Middle East and Africa Rheumatology Market Forecasts and Analysis - By Drug Class
10.4.4 Middle East and Africa Rheumatology Market Forecasts and Analysis - By Disease Indication
10.4.5 Middle East and Africa Rheumatology Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Rheumatology Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Rheumatology Market
10.4.6.1.1 South Africa Rheumatology Market by Drug Class
10.4.6.1.2 South Africa Rheumatology Market by Disease Indication
10.4.6.1.3 South Africa Rheumatology Market by Distribution Channel
10.4.6.2 Saudi Arabia Rheumatology Market
10.4.6.2.1 Saudi Arabia Rheumatology Market by Drug Class
10.4.6.2.2 Saudi Arabia Rheumatology Market by Disease Indication
10.4.6.2.3 Saudi Arabia Rheumatology Market by Distribution Channel
10.4.6.3 U.A.E Rheumatology Market
10.4.6.3.1 U.A.E Rheumatology Market by Drug Class
10.4.6.3.2 U.A.E Rheumatology Market by Disease Indication
10.4.6.3.3 U.A.E Rheumatology Market by Distribution Channel
10.4.6.4 Rest of Middle East and Africa Rheumatology Market
10.4.6.4.1 Rest of Middle East and Africa Rheumatology Market by Drug Class
10.4.6.4.2 Rest of Middle East and Africa Rheumatology Market by Disease Indication
10.4.6.4.3 Rest of Middle East and Africa Rheumatology Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Rheumatology Market Overview
10.5.2 South and Central America Rheumatology Market Forecasts and Analysis
10.5.3 South and Central America Rheumatology Market Forecasts and Analysis - By Drug Class
10.5.4 South and Central America Rheumatology Market Forecasts and Analysis - By Disease Indication
10.5.5 South and Central America Rheumatology Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Rheumatology Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Rheumatology Market
10.5.6.1.1 Brazil Rheumatology Market by Drug Class
10.5.6.1.2 Brazil Rheumatology Market by Disease Indication
10.5.6.1.3 Brazil Rheumatology Market by Distribution Channel
10.5.6.2 Argentina Rheumatology Market
10.5.6.2.1 Argentina Rheumatology Market by Drug Class
10.5.6.2.2 Argentina Rheumatology Market by Disease Indication
10.5.6.2.3 Argentina Rheumatology Market by Distribution Channel
10.5.6.3 Rest of South and Central America Rheumatology Market
10.5.6.3.1 Rest of South and Central America Rheumatology Market by Drug Class
10.5.6.3.2 Rest of South and Central America Rheumatology Market by Disease Indication
10.5.6.3.3 Rest of South and Central America Rheumatology Market by Distribution Channel
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL RHEUMATOLOGY MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. RHEUMATOLOGY MARKET, KEY COMPANY PROFILES
13.1. ABBVIE INC.
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. BRISTOL-MYERS SQUIBB COMPANY
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. PFIZER INC.
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. MERCK AND CO., INC.
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. AMGEN INC.
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. NOVARTIS AG
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. JANSSEN PHARMACEUTICALS, INC.
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. SANOFI
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. GENENTECH, INC.
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
1. AbbVie Inc.
2. Bristol-Myers Squibb Company
3. Pfizer Inc.
4. Merck & Co., Inc.
5. Amgen Inc.
6. Novartis AG
7. Janssen Pharmaceuticals, Inc.
8. Sanofi
9. Genentech, Inc.
10. Takeda Pharmaceutical Company Limited
11. Johnson & Johnson Private Limited
12. F. Hoffmann-La Roche Ltd
13. UCB S.A.
14. Gilead Sciences, Inc.
15. Boehringer Ingelheim International GmbH
16. Regeneron Pharmaceuticals Inc.
17. Eli Lilly and Company
18. Qiagen NV
19. Euro Diagnostica AB
20. Antibodies Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For